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Background: Aerosolized therapeutics hold great potential for effective treatment of various diseases including
lung cancer. In this context, there is an urgent need to develop novel nanocarriers suitable for drug delivery by
nebulization. To address this need, we synthesized and characterized a biocompatible drug delivery vehicle
following surface coating of Fe3O4 magnetic nanoparticles (MNPs) with a polymer poly(lactic-co-glycolic acid)
(PLGA). The polymeric shell of these engineered nanoparticles was loaded with a potential anti-cancer drug
quercetin and their suitability for targeting lung cancer cells via nebulization was evaluated.
Results: Average particle size of the developed MNPs and PLGA-MNPs as measured by electron microscopy was 9.6
and 53.2 nm, whereas their hydrodynamic swelling as determined using dynamic light scattering was 54.3 nm and
293.4 nm respectively. Utilizing a series of standardized biological tests incorporating a cell-based automated image
acquisition and analysis procedure in combination with real-time impedance sensing, we confirmed that the
developed MNP-based nanocarrier system was biocompatible, as no cytotoxicity was observed when up to 100 μg/ml
PLGA-MNP was applied to the cultured human lung epithelial cells. Moreover, the PLGA-MNP preparation was
well-tolerated in vivo in mice when applied intranasally as measured by glutathione and IL-6 secretion assays after 1, 4,
or 7 days post-treatment. To imitate aerosol formation for drug delivery to the lungs, we applied quercitin loaded
PLGA-MNPs to the human lung carcinoma cell line A549 following a single round of nebulization. The drug-loaded
PLGA-MNPs significantly reduced the number of viable A549 cells, which was comparable when applied either by
nebulization or by direct pipetting.
Conclusion: We have developed a magnetic core-shell nanoparticle-based nanocarrier system and evaluated the
feasibility of its drug delivery capability via aerosol administration. This study has implications for targeted delivery of
therapeutics and poorly soluble medicinal compounds via inhalation route.
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The development of nanoparticles as controlled drug de-
livery and disease detection systems has emerged as one
of the most promising biomedical and bioengineering
applications of nanotechnology. Magnetic nanoparticles,
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reproduction in any medium, provided the ornanoparticles (MNPs) and their multifunctionalized
counterparts are an important class of nanoscale mate-
rials that have attracted great interest for their potential
applications in drug delivery and disease diagnosis [1-5].
Owing to the recent advances in synthesis and surface
modification technologies, a variety of new potential
applications have become feasible for this class of nano-
materials that may revolutionise current clinical diagnos-
tic and therapeutic techniques.
The well-developed surface chemistry of Fe3O4 MNPs
allows loading of a wide range of functionalities, such asLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 A schematic model of drug-loaded magnetic core-shell
nanostructures.
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their surfaces. It is now possible to fine-tune the physical
parameters of MNPs, such as size, shape, crystallinity,
and magnetism [3,4]. Furthermore, MNPs have the po-
tential for replacement or modification of the coating
materials post-synthesis allowing tailoring of the nano-
particle’s surface charge, chemical groups, and overall
size [4-6]. Due to their unique physicochemical proper-
ties and ability to function at the cellular and molecular
level of biological systems, MNPs are being actively
investigated as the next generation of targeted drug de-
livery vehicle. The design of such drug delivery systems
requires that the carriers be capable of selectively relea-
sing their payloads at specific sites in the body and
thereby treat disease deliberately without any harmful ef-
fect on the healthy tissues. In this regard, MNPs repre-
sent a promising option for selective drug targeting as
they can be concentrated and held in position by means
of an external magnetic field. This allows high dose
drug-loads to be delivered to a desired target tissue
while minimizing the exposure of healthy tissues to the
side effects from highly toxic drugs, e.g. chemotherapeu-
tic agents. In addition, preclinical and clinical studies
have proven them to be safe and some formulations are
now FDA approved for clinical imaging and drug deli-
very [7]. In particular, MNPs are being extensively uti-
lized as a magnetic resonance imaging contrast agents to
detect metastatic infestation in lymph nodes (such as
CombidexW, ResovistW, EndoremW, SineremW), give in-
formation about tumor angiogenesis, identify dangerous
atherosclerosis plaques, follow stem cell therapy, and in
other biomedical research [8-11]. Further, functionalized
multimodal MNPs are being widely explored for nume-
rous other biomedical applications including magnetic
guidance of drugs encapsulated by magnetic particles to
target tissues (for example tumor) where they are
retained for a controlled treatment period [2,12-22].
Thus, fabrication of MNPs as drug conjugates has the
potential to greatly benefit inflammatory disease and
cancer treatments, and diagnostics.
Aerosolised therapeutics has emerged as a promising
alternative to systemic drug delivery for the treatment or
prevention of a variety of lung diseases such as asthma,
chronic obstructive pulmonary disease, respiratory infec-
tion, and lung cancer [23-26]. An aerosol-mediated ap-
proach to lung cancer therapy holds promise as a means
to improve therapeutic efficiency and minimize un-
wanted systemic toxicity. A number of drugs have been
investigated in vitro, in animal models and in human
trials as targeted aerosol chemotherapy for lung cancer
[25-31]. A range of nebulizer systems designed for indivi-
dualised and controlled preparations of therapeutic aero-
sols have been developed and validated (e.g. Aerogen’s
AeronebW Pro nebuliser) for aerosol therapy.The aim of this work was to establish a biocompatible
MNP-based drug delivery system suitable for nebuliza-
tion and inhalation targeting of therapeutics for the
treatment of lung diseases. The schematic structure of
the nanocarrier-drug composite is given in Figure 1. In
order to improve the dispersion in aqueous medium, sta-
bility against oxidation and biocompatibility of the deli-
very system, MNP surface was coated with a biopolymer
poly(DL-lactic-co-glycolic acid) (PLGA). In this study,
we selected a poorly soluble flavonoid quercetin to act
as a model drug, since it has demonstrated the potential
for growth inhibition of a variety of human cancers in-
cluding lung cancer [32,33]. The biocompatibility of the
developed nanocarrier system was tested in vitro and
in vivo, and the feasibility of a novel vibrating mesh ne-
bulization technique was investigated for the delivery of
drug-loaded MNPs to the cultured human lung cancer
cells. Thus, to our knowledge, this is the first study that
reports the potential of magnetic core-shell nanoparti-
cles loaded with a poorly soluble compound quercetin
for aerosol delivery by nebulization.Results
Preparation and characterization of surface engineered
MNPs
As evident from the analysis using transmission electron
microscopy (TEM) the average size of the uncoated MNPs
was 9.6 ± 1.3 nm, which was increased to 53.2 ± 6.9 nm
following coating with PLGA (Figure 2A). The dynamic
light scattering (DLS) measurements showed that the
average hydrodynamic diameter of MNP and PLGA-MNP
was 54.3 ± 8.7 nm and 293.4 ± 31.9 nm respectively. Mag-
netisation measurement of MNP was confirmed by its
superparamagnetic properties (Figure 2B). After purifica-
tion, a stock solution of 1 mg/ml was made for both the
MNP preparations and stored at room temperature. The
PLGA-MNP samples were stable in phosphate buffered
saline (PBS) and in physiological buffers.
MNP (9.6 ± 1.3 nm)
100 nm






























Figure 2 TEM images and magnetisation curve of initial MNPs. A. MNPs or PLGA coated MNPs (PLGA-MNP) were imaged by TEM and
presented. The average size of both the MNPs was measured as indicated on the corresponding images. B. Magnetisation curve of initial Fe3O4
MNP at room temperature.
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To investigate the biological safety of the developed
nanocarriers, the cell-MNP interaction by means of cel-
lular accumulation and their cytocompatibility on
human A549 lung epithelial cells was performed in vitro.
Initially we examined the morphology of A549 cells
exposed to MNP or PLGA-MNP (50 μg/ml each) for 24 h
by a cell-based automated microscope. Compared to the
control untreated cells, no detectable change in the gross
structure of the cytoskeletal protein actin (Figure 3A,
fluorescent images) or the morphology of cells exposed to
MNP or PLGA-MNP were detected (Figure 3A, bright
field images). The overall shapes and sizes of cells and nu-
clei were within the normal variation range and there were
no signs of cellular or nuclear abnormalities, membrane
bound vesicles, or cell rupture (Figure 3A). No significant
change in the cell morphology parameters including cell
and nuclear areas and fluorescent intensities was observedfollowing exposure to MNP or PLGA-MNP as compared
to that with untreated cells. Cellular accumulation of
MNP or PLGA-MNP was detected in treated cells
(Figure 3A, brightfield images in the middle panel and
insets in the right panel). We quantified the number of
cells with accumulated MNPs over time, which included
internalized MNPs and MNPs adhering to the cell surface,
by In Cell Investigator software (GE Healthcare, UK).
Results showed a time-dependent increase in the cellular
association of MNPs, where more than 50% cells with
accumulated MNPs at 4 h and over 75% cells with accu-
mulated MNPs at 8 h and 24 h were detected (Figure 3B).
The cytocompatibility analysis of MNP and PLGA-
MNP in A549 cells by high content screening (HCS)
demonstrated that both the MNP preparations were
non-toxic (<10% reduction in viable cell number) at con-
centrations up to 100 μg/ml (Figure 3C). However, a
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Figure 3 Cellular accumulation and cytocompatibility analysis of MNPs in A549 cells. A. A549 cells growing on 96-well tissue culture plates
were incubated without or with 50 μg/ml MNP or PLGA-MNP for 24 h, washed and fixed. Adherent cells were fluorescently stained with
rhodamine-phalloidin (red) to visualize cellular cytoskeleton actin and with Hoechst (blue) to visualize nuclei. Fluorescent or bright-field images
acquired using an automated microscope IN Cell Analyzer-1000 are presented in the left or middle panels. Right panels show corresponding
magnified images indicated by box in the middle panels. B. A549 cells growing on 96-well tissue culture plates were exposed to 50 μg/ml MNP
for up to 24 h and imaged by IN Cell Analyzer-1000. Percentage of cells with accumulated particles were quantified by IN Cell Investigator
software and presented. *p < 0.05 compared to untreated control. C. A549 cells growing on 96-well tissue culture plates were incubated with
various concentrations (ranging from 10 to 250 μg/ml) of MNP or PLGA-MNP for 24 h, washed and fixed. Cells were treated with 1 μg/ml
quantum dots as a toxicity control (+ve control). HCS biocompatibility analysis was performed using IN Cell Analyzer-1000 equipped with
Investigator software by quantifying cell adherence to the plates. Values in the plotted line graph are fold change in viable cell numbers ± SEM of
three independent experiments in triplicate from five randomly selected fields/well containing at least 300 cells. *p < 0.05 compared to untreated
control. D. Real-time electric impedance sensing measurements of A549 cells treated with 100 μg/ml MNP, PLGA-MNP or 10 μg/ml nocodazole
(as a toxicity control). Each data point is the mean Cell Index ± SEM of technical triplicates. A representative plot of three independent
experiments is shown.
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MNP preparations was observed at a high concentration
of 250 μg/ml (Figure 3C). We further evaluated the bio-
compatibility of MNP and PLGA-MNP (100 μg/ml each)
in A549 cells in real-time for up to 76 h using a whole
cell-based electrical impedance sensing technique utiliz-
ing xCELLigance instrument (Roche Applied Science,
West Sussex, UK). Untreated cells seeded onto the gold
electrode array of the impedance assay E-plates (suppliedby Roche Applied Science, West Sussex, UK) at a density
of 5 × 103 cells/well showed a continuous increase in im-
pedance (expressed as an arbitrary unit Cell Index) over
time as the cells attach, spread and form a stable con-
fluent monolayer on the surface of the E-plate
(Figure 3D). When A549 cells were treated with un-
coated MNPs (100 μg/ml) at 20 h after cell seeding onto
the E-plate, a low level of decrease in the Cell Index was
detected over time; whereas or PLGA-MNPs did not
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untreated cells (Figure 3D). In contrast, a sharp decrease
in the Cell Index was detected when A549 cells were
treated with a toxic compound nocodazole (Figure 3D).
In vivo biocompatibility analysis of engineered MNPs
The biocompatibility of MNPs surface engineered with a
PLGA polymer coat was also assessed in vivo using a
mouse model. Homogenised mouse lung samples were
assayed for total glutathione levels (both GSH and
GSSH) as an indicator of oxidative stress after 1, 4, and
7 days post-exposure to uncoated MNP, PLGA-MNP or
lipopoysaccharide (LPS, used as a positive control). Lung
samples obtained 1 day after intranasal administration
showed a dramatic increase in the glutathione levels in
the case of all samples (Figure 4A), which may possibly
be attributed to the invasive nature of intratracheal ad-
ministration. However, the glutathione levels in the lung
tissue were reduced 4 days after treatment with MNP
or PLGA-MNP and continued to decrease thereafter
(Figure 4A). In contrast, glutathione levels in mice trea-
ted with LPS remained elevated over the 7 day test
period (Figure 4A). Analysis of IL-6 levels in bronchoal-
veolar lavage (BAL) fluid samples from treated mice
measured at 1, 4 and 7 days subsequent to intranasal
administration of the MNP formulations and the LPS
control (Figure 4B). After 1 day, a significant increase
in IL-6 levels in the case of the LPS control was
observed, but this returned to background level 4 days
post treatment, whereas mice treated with uncoated
MNP or PLGA-MNP displayed no significant increase
in IL-6 levels relative to naïve animals at any time
points post-treatment.Glutathione levels A
Figure 4 In vivo biocompatibility analysis of MNPs. A. Measurement of
intranasal delivery. Lungs were harvested from treated mice at 1, 4 and 7 d
positive control). B. Measurement of IL-6 levels in BAL fluid from mice treat
treated mice at 1, 4 and 7 days post-treatment with MNP, PLGA-MNP or LP
conditions.Efficacy analysis of quercetin-loaded MNPs delivered
in vitro by nebulization
We incorporated a model drug quercetin in the PLGA-
MNP and then characterized by photoluminescence be-
fore and after nebulization. No significant change in
intensity and position (no shift) of the bands in the
photoluminescence spectra (excited at 380 nm) was
detected due to nebulization, confirming that the parti-
cles were intact and not adversely affected by the process
of nebulization (Figure 5).
To evaluate the therapeutic efficacy of quercetin-
loaded PLGA-MNPs, they were applied to the human
A549 lung carcinoma cells. A549 cells seeded in 96-well
plates were exposed to varying doses of PLGA-MNP or
quercetin-loaded PLGA-MNP (ranging from 31.25 μg/ml
to 250 μg/ml) by direct pipetting or by nebulization and
incubated for 24 h. The ability of quercetin present in the
PLGA-MNP to cause cell death of A549 cells was analysed
using HCS assay by quantifying the number of viable ad-
herent cells (Figure 6). No significant change in the num-
ber of adherent cells was observed following exposure to
PLGA-MNP (Figure 6). In contrast, quercetin-loaded
PLGA-MNP, applied to cells either by direct pipetting
(Figure 6A) or by nebulization (Figure 6B) and incubated
for 24 h, significantly reduced the number of viable A549
cells. These data confirmed the in vitro therapeutic effi-
cacy of the quercetin-loaded PLGA-MNP.
Discussion
There is currently significant worldwide effort to de-
velop, fabricate and characterize novel nanoscale mate-
rials for a variety of novel applications. In the present
work, we have developed procedures to prepare novelIL-6 levelsB
total glutathione levels in lung tissue from mice treated with a single
ays post-treatment with uncoated MNP, PLGA-MNP or LPS (used as a
ed with a single intranasal delivery. BAL fluid was obtained from
S. Data are mean ± SEM of at least 3 animals under each treatment


























Figure 5 Photoluminescence spectra of quercetin-loaded PLGA-MNP before and after nebulization. Spectra show normalised
photoluminescence (PL) intensities (a.u., arbitrary units) against wavelength (nm).
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for biomedical applications. Biocompatibility of the
developed MNPs was characterized in vitro (the in-
fluence of MNPs was assessed in terms of cell viability,
cellular and nuclear morphology, and observations of
actin cytoskeleton) and in vivo (the influence of MNPs
on glutathione and IL-6 secretion in mice). The deve-
loped MNPs were successfully loaded with a promising
anti-cancer drug quercetin. Further, in this study we
described a novel method of drug-loaded nanoparticle


































* * * *
A    Applied by direct pipetting 
Figure 6 Comparative analysis of the efficacy of quercitin-loaded PLG
nebulization. A549 cells growing on 96-well tissue culture plates were exp
empty or quercitin-loaded PLGA-MNP by direct pippetting (A) or nebulizat
and fixed. HCS assay was performed using IN Cell Analyzer-1000 equipped
Values in the plotted as line graph are fold change in viable cell numbers ±
randomly selected fields/well containing at least 300 cells. *p < 0.05. Querce
solubility.proof-of-concept nanoplatform documented in the
present study can further be exploited to load function-
alities onto the MNP surfaces via various mechanisms
with broad implications for pharmacotherapies, drug de-
livery and molecular imaging.
A targeted drug delivery system requires the design of
carriers capable of selectively releasing their payloads at
specific sites in the body. Although a number of nano-
size materials are being exploited for drug delivery pur-
poses including for example PLGA nanoparticles [34,35],


































* * * * 
B    Applied by nebulization 
A-MNP delivered to A549 cells via direct pippetting or
osed to various concentrations (ranging from 10 to 250 μg/ml) of
ion (B). Following treatment, cells were incubated for 24 h, washed
with Investigator software by quantifying cell adherence to the plates.
SEM of three independent experiments in triplicate from five
tin alone could not be used as a control due to its poor aqueous
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attributes. In particular, they can be concentrated and
held in position with the aid of an external magnetic
field. The deposition, accumulation, and retention of
drug-conjugated MNPs in target tissue can thus be
enhanced by magnetic guidance. Such magnetic target-
ing allows very concentrated drug doses to be delivered
to specific area while minimizing the exposure of healthy
tissues to uncontrollable highly toxic therapeutic sub-
stances; e.g. chemotherapeutic agents. Moreover, the
superparamagnetic behaviour of MNPs provides multi-
functional effects such as controlled heating capability
under an alternating magnetic field, which has demon-
strated tremendous promise as theranostics for the de-
tection and treatment of cancer [7,9,36,37]. In addition,
iron oxides occur naturally in human heart, spleen and
liver [38], which supports the biocompatibility and non-
toxicity of MNPs at a physiological concentration. Due to
the above-mentioned favorable features and versatility, in
our opinion, Fe2O3 MNPs would serve as an excellent
core material for a nano carrier system particularly suit-
able for the controlled aerosol drug delivery.
To date a wide variety of MNPs have been developed
by several researchers, differing in size and type of coat-
ing materials used [7-13,39-42]. Some preparations are
currently in preclinical or clinical use in intracellular
hyperthermia treatments and MRI contrast agents [7,9].
It is important to note that in order to improve the size
distribution of MNPs and prevent their aggregation in
aqueous solution these nanoparticles have to be coated
with materials that keep particles apart. However, there
is quite contradictory information on the effect of mag-
netic nanoparticles - biopolymer core-shell structures on
cytotoxicity. It has been suggested that upon internaliza-
tion, the coating shell on the MNPs may be broken
down yielding particle chains and aggregates, which may
influence biological processes [42,43]. In this study, we
modified the surface of Fe3O4 MNPs by coating them
with a biocompatible polymeric material PLGA, which
has been proven to be beneficial for nanoparticle coating
purposes with no measurable toxicity reported [42,44].
In order to evaluate the biocompatibility of developed
MNPs, we performed a series of in vitro assays using a
human lung alveolar epithelial cell line A549 and in vivo
studies using normal Balb/c mice. The carcinoma-
derived A549 cells are a well-characterised in vitro lung
epithelial model and have been extensively used for
assessing cytotoxicity, including nanomaterials-induced
cytotoxicity [45-47]. Additionally, A549 cells display
similar uptake and toxicity of nanoparticles as compared
to normal primary lung epithelial cells, although both
cell types respond differentially for the release of cyto-
kines involved in inflammatory reactions [48]. Based on
these reports and our data from in vitro as well asin vivo experiments presented here, we expect that the
developed MNPs will have similar effect(s) on normal
lung epithelial cells in terms of their cytocompatibility.
However, a detailed characterization of MNPs on normal
lung cells should be performed before their potential
clinical applications in drug delivery.
We employed the use of HCS in combination with an
impedance-based assay for the biocompatibility analysis
of MNP preparations. The HCS assay utilizes a novel
quantitative imaging technique and offers rapid analysis
of toxicity (if any) at cellular level [46,47]; whereas, im-
pedance sensing allows a kinetic profile of cytotoxicity
(if any), and maps the processes that cells undergo when
challenged with nanoparticles such as MNPs [49,50].
Since the insulating properties of cells are based on
whole cell structure, cellular responses such as cell
death, proliferation, spreading and attachment can be
detected by impedance measurements [49,50]. This cell-
based label-free non-invasive detection method thus not
only provides toxicity data, but also can identify a time-
frame during which further targeted analysis can be per-
formed. Both HCS and impedance measurement assays
confirmed that MNPs developed in the present work
were not toxic to A549 cells up to a concentration of
100 μg/ml, although a high concentration of 250 μg/ml
were moderately toxic.
As described, we selected quercetin as a model drug.
Quercetin is one of the most prevalent as well as thor-
oughly studied dietary flavonoids with several biological
and pharmacological properties. Evidence indicates that
quercetin has a variety of anti-cancer mechanisms, in-
cluding anti-proliferative, pro-apoptotic, cell signalling
effects, and growth factor suppression, as well as poten-
tial synergism with some chemotherapeutic agents
[32,51]. Quercetin also exhibits anti-inflammatory, anti-
oxidant, and anti-viral activities [33]. Moreover, it has a
role in reversing drug resistance, re-sensitizing cancer
cells to some chemotherapeutic agents and in potentia-
ting the effectiveness of some chemotherapeutic agents
[52]. However, realizing the therapeutic benefits of quer-
cetin in the clinical setting is hampered by its low solu-
bility (~ 2%) in aqueous medium and poor absorption in
the body. Thus, the low bioavailability and poor solubi-
lity in aqueous medium are major concerns associated
with the therapeutic application of quercetin [51,52].
Similar limitations apply to experimental evaluation of
quercetin’s effect on cultured human cells in biological
medium, and therefore quercetin alone could not be
used for comparison in the present study. The MNP car-
rier system developed in the present study was appro-
priate in this regard; and therefore, the ability of
quercetin to inhibit lung cancer cell growth was evaluated
in comparative analysis of non-functionalized and drug-
loaded PLGA-MNPs.
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of GSH in lung tissue, an indicator of oxidative stress
[53], but this was not observed to be consistently ele-
vated over the follow-up period of 7 days unlike the LPS
control. IL-6, which acts as both a pro-inflammatory and
anti-inflammatory cytokine [54], and is secreted by T-
cells and macrophages to stimulate an immune response
during infection and after tissue trauma was also investi-
gated as a marker of immune response. The LPS caused
a significant increase in IL-6 levels in BAL samples 1
day after treatment as expected, but this was not repli-
cated in the case of the MNPs. In fact the IL-6 levels in
BAL samples from mice exposed to MNP or PLGA-
MNP were comparable to those observed after adminis-
tration of normal saline solution in control groups. IL-6
levels in blood plasma (data not shown) were of a much
lower level and more variable indicating the localized
nature of the response in the pulmonary tissue. This is
in agreement with the in vitro results discussed above.
Previously it has been shown that intranasal delivery of
iron nanoparticles can lead to an increase in inflamma-
tory markers including IL-6 [55]. PLGA particles them-
selves have been shown to have a low propensity to
cause immune responses when delivered directly to the
lung [56]. The biocompatible MNPs developed in this
work may also be potentially exploited for targeting
using external magnetic fields as demonstrated recently
in nebulized mice [57].
Regional chemotherapy has been proposed as a treat-
ment modality in a number of disease situations in order
to increase exposure of the target tissues to the drug,
while minimising systemic side-effects. Administration
of drugs directly via inhalation allows localized drug de-
livery to the lungs and airways with smaller doses and
minimal systemic toxicity [58]. An additional reason for
maximising total deposition and targeting drugs to their
desired location is to improve the cost effectiveness of
drug delivery [59]. There is now increasing evidence to
support the role of inhalation therapeutics in the treat-
ment of various lung diseases. For example in lung can-
cer, nebulization therapeutics could be useful in 1)
unresectable bronchioloalveolar carcinoma or main
bronchus carcinoma with limited invasion, 2) endobron-
chial tumour relapse after surgery, 3) in situ carcinoma
or synchronous, or 4) metachronous lesions in patients
where a lesion has already been detected. However, few
studies have documented the feasibility of applying
nanotechnology for inhalation delivery of anticancer
agents [60]. Therefore, new aerosol delivery technologies
are currently being developed to meet these goals of
improved targeting, reduced waste and improved patient
compliance. Vibrating mesh-based nebulizers (e.g., Aerogen
nebulizer) can allow for sensitive tracking of flows or
pressures during breathing manoeuvres and offer thepotential for high efficiency delivery of aerosolized
medications. These nebulizers have been used for
breath actuated high efficiency aerosol delivery during
mechanical ventilation of humans and rodents [61,62].
Appropriate aerosol actuation during defined portions
of the breath, allow for aerosol-free intervals, if
required, thus avoiding drug deposition in the dead
space of the patient interface, and even targeting of spe-
cific potions of the lung, e.g., introducing the aerosol in a
small bolus at the end of inspiration to target the upper
airways. Although the customizable vibrating mesh-type
nebulizers have not been applied clinically to deliver
MNP-based cancer therapeutics to the lung heretofore,
the present study provides proof of principle for such
targeting.
Conclusion
Here, we report the development of a surface engineered
magnetic core-shell nanoparticle-based drug delivery
system designed for aerosol therapy of lung diseases. We
present a series of in vitro and in vivo investigations that
were carried out to evaluate the biocompatibility of the
developed nanocarrier and the feasibility of pulmonary
delivering quercetin-loaded MNPs by nebulization. The
data presented here demonstrate inhibition of lung
adenocarcinoma growth by aerosol delivery of quercetin
loaded in the PLGA-MNPs. Further in vivo studies are
required to determine the optimal dosage and frequency
of aerosol administrations and to assess the anticancer
effect of nanoencapsulated aerosolised chemotherapy on
established tumours. With the on-going efforts to en-
hance MNP’s targeting ability, endow more functions
and administration routes, their future holds great
promise for advanced drug delivery applications.
Methods
MNP preparation
FeCl2 (12 mM) and FeCl3 (24 mM) were dissolved in 25
ml HCl (0.4 M) solution. The precursors were added
drop-wise to a degassed 0.5 M NaOH solution at 40°C.
The mixture was stirred for 1 h, and then cooled to
room temperature. The MNPs were subjected to mag-
netic separation and then washed repeatedly with water
until neutral pH was reached. Next, MNPs were surface
coated by o/w emulsification of 4 ml acetone:dichloro-
methane (1:2) contained 100 mg PLGA (Sigma-Aldrich
Ireland Ltd., Wicklow, Ireland), 50 μl of 10 mg/ml MNP,
and 20 mg quercetin (where appropriate). The mixture
was added to 12 ml of 0.3% polyvinyl alcohol aqueous
solution (15,000 g/M). The mixture was emulsified
under a sonic tip for 30 seconds, the emulsion was then
added to 50 ml of 0.3% polyvinyl alcohol solution and
stirred overnight to remove the organic phase. The sus-
pension was then centrifuged at 3000 g and subsequently
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polyvinyl alcohol.
Transmission electron microscopy (TEM)
Samples for TEM were prepared by deposition and dry-
ing of a drop of the powder dispersed in ultrapure water
onto a formvar coated 400 mesh copper grids. High
resolution TEM images were acquired using an FEI-
Titan TEM.
Dynamic light scattering (DLS) measurements
DLS measurements were performed using a Malvern
Zetasizer Nano Series V5.10. The concentration of sam-
ples used for these measurements typically corresponded
to an approximate absorbance of 0.2 nm. Three mea-
surements were usually taken for each sample and then
averaged.
Cell culture and treatments
Human alveolar epithelial cells (A549 cell line, European
Collection of Cell Cultures, Salisbury, UK) were cultured
as described [47]. Briefly, cells were cultured in GibcoW
Ham’s F12 medium supplemented with 10% (v/v) foetal
bovine serum, 10,000U penicillin and 10 mg/ml strepto-
mycin in 5% CO2 at 37°C in a humidified incubator. For
experimentation, cells were seeded in 96-well plates at
the density of 4 × 103 cell/well and allowed to grow over-
night prior to treatment. Nanoparticles were dispersed
in PBS to make a stock solution of 1 mg/ml and then
diluted in cell culture medium prior to administration to
the cells. Serial dilutions were established by mixing
equal volumes of particle suspension and cell culture
medium followed by vigorous vortexing, and applied to
the cells immediately. The cell culture media and sup-
plements were from Life Technologies Corporation (Bio-
Sciences, Dublin, Ireland).
High Content Screening (HCS) and analysis
HCS protocols for nanotoxicity studies have been opti-
mized and established in our laboratory as described
[46,47,63-68]. Briefly, A549 cells were seeded in 96-well
plates (4 × 103 cells/well), exposed to various concentra-
tions of MNP preparations for varying time-points (as
indicated in the text and corresponding figure legends)
at 37°C and 5% CO2. After washing three times with
PBS, cells were fixed by incubating them for 20 min with
3% paraformaldehyde. Adherent cells were then fluores-
cently stained with rhodamine labelled phalloidin to
visualize the cellular morphology and Hoechst to
visualize the nuclei. Plates were scanned (five randomly
selected fields/well) using an automated microscope IN
Cell Analyzer 1000 (GE Healthcare, UK) and the acquired
images were automatically analysed by IN Cell Investigator(version 1.6) software using multi-parameter cytotoxicity
bio-application module (GE Healthcare, UK).
Real-time impedance sensing
The dynamic monitoring of electrical impedance (which
depends on cell number, degree of adhesion, spreading
and proliferation of the cells) to determine cytotoxic
effects of MNPs was performed using Real-Time Cell
Analyzer DP instrument as per manufacturer’s instruc-
tions (xCELLigance system, Roche Applied Science,
West Sussex, UK) and described previously [47,68,69].
Briefly, A549 cells were seeded at a density of 5 × 103
cells/well in 100 μl medium in the E-Plates 16 (cross
interdigitated micro-electrodes integrated on the bottom
of 16-well tissue culture plates by micro-electronic sen-
sor technology) and allowed to attach onto the electrode
surface over time. The electrical impedance was
recorded every 15 minutes. At 20 h time point, when
cells adhered to the well properly, they were treated with
MNP preparations in triplicate and monitored for a fur-
ther 76 h to record changes in cell behaviour. To ensure
the MNP preparations did not interfere with the impe-
dance measurements, control wells containing medium
only and corresponding MNP samples were run in paral-
lel. The cell impedance, expressed as an arbitrary unit
called the ‘Cell Index’, were automatically calculated on
the xCELLigence system and converted into growth
curves.
MNP delivery to lung epithelial cells by nebulization
The delivery of the engineered MNP preparations to
A549 lung cancer cells by nebulization was performed
using a proprietary vibrating mesh-type nebulizer
(AeronebW Pro nebulizer system, Aerogen, Galway Business
Park, Ireland) (volumetric mean diameter 3.65 μm and
nebulizer flow rate 0.190 ml/min with normal saline) as per
manufacturer’s instructions. Briefly, A549 cells were seeded
in 96-well plates (4 × 103 cells/well) and allowed to adhere
for 24 h. Cells were exposed to nanoparticles either by di-
rectly pip petting or nebulizing media containing varying
concentrations of MNPs (as indicated in the text and corre-
sponding figure legends) into the wells. Following exposure,
cells were incubated for a further 24 h and the number of
viable adherent cells was quantified by HCS assay as
described above.
In vivo biocompatibility testing of MNPs
Six to eight week old female Balb/c mice (Harlan, UK)
were allowed to acclimatise for two weeks before the ini-
tiation of the study. For all the in vivo experiments, ethi-
cal approval was obtained from the internal Ethics
Committee of University College Cork, Ireland. Mice
were treated intranasally with 50 μl solution containing
1 mg/ml of MNP preparations. LPS (50 μg/ml) was
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known to be a potent initiator of acute lung injury [70].
Mice were euthanized at 1, 4 and 7 days post-treatment
and the lungs were excised. Tissue was homogenised in
50 mM MES buffer followed by centrifugation. The
supernatant was then deproteinated and glutathione
levels were determined using a Glutathione Assay Kit as
per manufacturer’s protocol (Cayman Chemical Com-
pany, MI, USA). BAL fluid was obtained to assess the
IL-6 levels. Mice euthanized at 1, 4 and 7 days post-
treatment were dissected to expose the trachea. A small
incision was made in the trachea and 1 ml of cold sterile
saline was loaded into the lung and immediately
removed. This was centrifuged at 3000 g for 10 min to
remove cellular material. The supernatant was assayed
for IL-6 levels using an IL-6 ELISA kit as per manufac-
turer’s protocol (eBioscience, UK).
Statistical analysis
Each experiment was repeated a minimum of three
times. The data are expressed as mean ± SEM. For com-
parison of two groups, p-values were calculated using
the two-tailed student’s t-test. In all cases, statistical sig-
nificance was accepted at a level of p-values < 0.05.
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